CPHA Canvax
CPHA Canvax

"As of early 2009, the Canadian vaccine landscape mirrors the highly concentrated structure of the global vaccine marketplace, with the “top tier” vaccine companies currently including GlaxoSmithKline Canada, Merck Canada Ltd., Novartis, Pfizer Canada (formerly Wyeth Pharmaceuticals Canada), and sanofi pasteur. Other industry players in Canada include Solvay Pharma Inc., as well as the smaller vaccine developers Medicago, Immunoaccine Inc., and Variation Biotechnologies Inc., among others. The vaccine research community encompasses the discovery and clinical research departments of the lead industry players, as well as a broad array of player engaged in early-stage vaccine R&D at academic, hospital, and government laboratories and research institutions. Funded by a diverse group of major grant agencies, as well as private and public investors, Canada’s vaccine industry players make a significant contribution to the national economy, in terms of both job creation and investment in R&D. Hence the vaccine sector should be actively promoted and fostered by stakeholders across all levels of the research community, the business/investment community, and government". - The Current Canadian Vaccine Environment (Part 2 of Vaccine White Paper Series)


Web link

The Current Canadian Vaccine Environment

Related Resources

Bookmark

Background Knowledge

Link

Category

Vaccine Safety and Development,Research and Development,Vaccine Development Vaccine Safety and Development
Research and Development
Vaccine Development

0 Comments

Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.